🔎 Trials Near Me

Home › Kanser sa Pantog › California › San Francisco

Pag-aaral pangklinika para sa Kanser sa Pantog sa San Francisco, CA

Isang pag-aaral para sa Kanser sa Pantog ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa San Francisco. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)

Nagre-recruitPhase 1/2
  • UCSF Medical Center at Mission Bay ( Site 5044), San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT07232602

Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

Nagre-recruitPhase 1/2
  • University of California, San Francisco, San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06470282

Imaging Study of [89Zr]DFO-YS5 for Cancer Detection

Nagre-recruitPhase 1
  • University of California, San Francisco, San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT07664397

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Nagre-recruitPhase 3
  • UCSF Medical Center at Mission Bay, San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07218380

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

Nagre-recruitPhase 1
  • UCSF Medical center Parnassus, San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT07217171

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Nagre-recruitPhase 2/3
  • Pacific Hematology Oncology Associates, San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 29, 2026 · NCT07106762

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Nagre-recruitPhase 2
  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Edad 8 pataas · Lahat ng kasarian · Na-update Hul 27, 2026 · NCT05503797

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Nagre-recruitPhase 2
  • UCSF Cancer Center MZ Phlebotomy, San Francisco
  • UCSF Mount Zion Phlebotomy, San Francisco
  • UCSF Parnassus Phlebotomy, San Francisco
  • at 3 pa
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 22, 2026 · NCT04879329

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

Nagre-recruitPhase 3
  • Research Site, San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 22, 2026 · NCT07720284

Predicting BCG Response

Nagre-recruitObservasyonal na pag-aaral
  • UCSF, San Francisco
Edad 18 hanggang 90 · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT04564781

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Nagre-recruitPhase 1
  • University of California San Francisco, San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 13, 2026 · NCT06778863

Blue Light Cystoscopy With Cysview® Registry

Nagre-recruitObservasyonal na pag-aaral
  • University of California, San Francisco, San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 18, 2025 · NCT02660645

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Nagre-recruitObservasyonal na pag-aaral
  • Massive Bio SYNERGY-AI site, San Francisco
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774

Pag-aaral para sa Kanser sa Pantog sa ibang lungsod

Iba pang pag-aaral sa San Francisco

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.